Testosterone Replacement
Therapy Litigation
O’Brien Law is actively involved in litigating cases involving AndroGel and Androderm against AbbVie and its subsidiaries, including the company formerly known as Watson Pharmaceuticals, then Actavis, then Allergan Inc.
When Testosterone Replacement Therapy (TRT) came to the market, it was approved only to treat a rare set of conditions. But, AbbVie and Watson promoted their AndroGel and Androderm beyond what they were approved to treat (i.e., off-label), telling men it would make them feel younger, have more energy, and improve libido and sexual performance.
But a dark side was lurking. Over the years, more and more mounting evidence showed a link between TRT and heart attacks and strokes. Finally, in 2015, FDA convened an Advisory Committee, ordered the manufacturers to put warnings on their labels, and ordered them to conduct a comprehensive safety study.
O’Brien Law represents people hurt by AbbVie’s and Watson’s bad conduct in marketing AndroGel and Androderm and in failing to warn about the drugs’ dangers.
